Glucocorticoid-induced osteoporosis

Women's Health

Volumn 2, Issue 1, 2006, Pages 65-74

  Kennedy, Courtney C ^a   Papaioannou, Alexandra ^a   Adachi, Jonathan D ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Bone mineral density; Epidemiology; Fractures; Glucocorticoid; Management; Osteoporosis; Pathophysiology

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCITONIN; CALCITRIOL; CALCIUM; ETIDRONIC ACID; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCALCIN; PREDNISOLONE; RISEDRONIC ACID; SALCATONIN; SEX HORMONE; VITAMIN D;

BONE DENSITY; BONE REMODELING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOSE RESPONSE; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; LOW DRUG DOSE; MOLECULAR MECHANICS; OSTEOCYTE; OSTEOLYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VERTEBRA FRACTURE;

EID: 33646801657     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.1.65     Document Type: Review

References (83)

1. Mathier MA, McNamara DM: Management of the patient after heart transplant. Curr. Treat. Options Cardiovasc. Med. 6(6), 459-469 (2004).
2. Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, Bustami T, Dyke DB: Immunosuppression: practice and trends. Am. J. Transplant. 4(Suppl. 9), 38-53 (2004).
3. NIH Consensus Development Panel on Osteoporosis: Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6), 785-795 (2001).
4. Caplan GA, Scane AC, Francis RM: Pathogenesis of vertebral crush fractures in women. J. R. Soc. Med. 87(4), 200-202 (1994).
5. Rubin MR, Bilezikian JP: Clinical review 151: the role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J. Clin. Endocrinol. Metab. 87(9), 4033-4041 (2002).
6. Lukert BP, Raisz LG: Glucocorticoid- induced osteoporosis: pathogenesis and management. Ann. Intern. Med. 112 (5), 352-364 (1990).
7. Van Staa TP, Leufkens HG. Abenhaim L, Begaud B, Zhang B, Cooper C: Use of oral corticosteroids in the United Kingdom. QJM 93(2), 105-111 (2000).
8. Chantler IW, Davie MW, Evans SE Rees JS: Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann. Rheum. Dis. 62(4), 350-352 (2003).
9. Cakir B, Odabasi E, Turan M, Guler S, Kutlu M: Secondary osteoporosis in women. A retrospective analysis. Arch. Gynecol. Obstet. 266(4), 214-217 (2002).
10. Khosla S, Lufkin EG, Hodgson SF, Fitzpatrick LA, Melton Q III: Epidemiology and clinical features of osteoporosis in young individuals. Bone 15(5), 551-555 (1994).
11. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102(2), 274-282 (1998).
12. Hansen LB, Vondracek SF: Prevention and treatment of nonpostmenopausal osteoporosts. Am. J. Health Syst. Pharm. 61(24), 2637-2654 (2004).
13. Van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG: Public health impact of adverse bone effects of oral corticosteroids. Br. J. Clin. Pharmacol. 51(6), 601-607 (2001).
14. Van Staa TP, Leufkens HG, Cooper C: The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13(10), 777-787 (2002).
15. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C: Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 39(12), 1383-1389 (2000).
16. Vestergaard P, Olsen ML, Paaske JS, Rejnmark L, Sorensen HT Mosekilde L: Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J. Intern. Med. 254(5), 486-493 (2003).
17. Ton FN, Gunawardene SC, Lee H, Neer RM: Effects of low-dose prednisone on bone metabolism. J. Bone Miner. Res. 20(3), 464-470 (2005).
18. Kanis JA, Johansson H, Oden A et al.: A meta-analysis of prior corticosteroid use and fracture risk. J. Bone Miner. Res. 19 (6), 893-899 (2004).
19. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C: Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15(6), 993-1000 (2000).
20. Walsh LJ, Lewis SA, Wong CA et al.: The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am. J. Respir. Crit. Care Med. 166 (5), 691-695 (2002).
21. Van Staa TP. Geusens P, Pois HA, de Laet C, Leufkens HG, Cooper C: A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 98(3), 191-198 (2005).
22. Aris R, Donohue JF, Ontjes D: Inhaled corticosteroids and fracture risk: having our cake and eating it too. Chest 127(1), 5-7 (2005).
23. Richy F, Bousquet J, Ehrlich GE et al.: Inhaled corticosteroids effects on bone in asthmatic and COPID patients: a quantitative systematic review. Osteporos. Int. 14(3), 179-190 (2003).
24. Vestergaard P, Rejnmark L, Moseldide L: Fracture risk associated with systemic and topical corticosteroids. J. Intern. Med. 257(4), 374-384 (2005).
25. Langhammer A, Norjavaara E, de Verdier MG, Johnsen R, Bjermer L: Use of inhaled corticosteroids and bone mineral density in a population based study: the Nord- Trondelag Health Study (the HUNT Study). Pharmacoepidemiol. Drug Saf. 13(8), 569-579 (2004).
26. Fujita, K, Kasayama S, Hashimoto J et al.: Inhaled corticosteroids reduce bone mineral density in early postmenopausal but not premenopausal asthmatic women. J. Bone Miner. Res. 16(4), 782-787 (2001).
27. Wong CA, Walsh LJ, Smith CJ et al.: Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 355(9213), 1399-1403 (2000).
28. Van Staa TP, Bishop N, Leufkens HG, Cooper C: Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos. Int. 15 (10). 785-791 (2004).
29. Van Staa TP, Leufkens HG, Cooper C: Use of inhaled corticosteroids and risk of fractures. J. Bone Miner. Res. 16 (3), 581-588 (2001).
30. Johannes CB, Schneider GA, Dube TJ, Alfredson TD, Davis KJ, Walker AM: The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. Chest 127(1), 89-97 (2005).
31. de Vries F, Van Staa TP, Bracke MS, Cooper C, Leufkens HG, Lammers JW: Severity of obstructive airway disease and risk of osteoporotic fracture. Eur. Respir. J. 25(5), 879-884 (2005).
32. Mortimer KJ, Harrison TW, Tattersfield AE: Effects of inhaled corticosteroids on bone. Ann. Allergy Asthma Immunol. 94(1), 15-21 (2005).
33. Leclerc N, Noh T, Khokhar A, Smith E, Frenkel B: Glucocorticoids inhibit osteocalcin transcription in osteoblasts by suppressing Egr2/ Krox20-binding enhancer. Arthritis Rheum. 52 (3), 929-939 (2005).
34. Patchan D, Loddenkemper K, Buttgereit F: Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 29(6), 498-505 (2001).
35. O'Brien CA, Jia D, Plotkin LI et al.: Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145(4), 1835-1841 (2004).
36. Weinstein RS, Jia D. Powers CC et al.: The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 145(4), 1980-1987 (2004).
37. Weinstein RS: Glucocorticoid-induced osteoporosis. Rev. Endocr. Metab. Disord. 2(1), 65-73 (2001).
38. Paz-Pacheco E, Fuleihan GE, LeBoff MS: Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. J. Bone Miner. Res. 10 (11), 1713-1718 (1995).
39. Canalis E, Bilezikian JP, Angeli A, Giustina A: Perspectives on glucocorticold- induced osteoporosis. Bone 34 (4), 593-598 (2004).
40. Bonadonna S, Burattin A, Nuzzo M et al.: Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur. J. Endocrinol. 152(2), 199-205 (2005).
41. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C: Androgens and bone. Endocr. Rev. 25(3), 389-425 (2004).
42. Compston JE: Sex steroids and bone. Physiol. Rev. 81(1), 419-447 (2001).
43. Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RS: Influence of glucocorticoids on human osteoclast generation and activity. J. Bone Miner. Res. 20(3), 390-398 (2005).
44. Clowes JA, Peet N, Eastell R: Glucocorticoid-induced osteoporosis. Curr. Opin. Rheumatol. 13(4), 326-332 (2001).
45. Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R: Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem. Biophys. Res. Commun. 318(1), 259-264 (2004).
46. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R: Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem. Biophys. Res. Commun. 329(1), 177-181 (2005).
47. Chang DJ, Ji C, Kim KK, Casinghino S, McCarthy TL, Centrella M: Reduction in transforming growth factor beta receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid. J. Biol. Chem. 273(9), 4892-4896 (1998).
48. Weinstein RS, Nicholas RW, Manolagas SC: Apoptosis of osteocytes in glucocorticold- induced osteonecrosis of the hip. J. Clin. Endocrinol. Metab. 85(8), 2907-2912 (2000).
49. Manolagas SC: Corticosteroids and fractures: a close encounter of the third cell kind. J. Bone Miner. Res. 15 (6), 1001-1005 (2000).
50. Van Staa TP, Laan RE Barton IP, Cohen S. Reid DM, Cooper C: Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48(11), 3224-3229 (2003).
51. Selby PL, Halsey JP, Adams KR et al.: Corticosteroids do not alter the threshold for vertebral fracture. J. Bone Miner. Res. 15 (5), 952-956 (2000).
52. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 44(7), 1496-1503 (2001).
53. Guideline Development Group for the Royal College of Physicians: Glucorticoid induced osteoporosis. Royal College of Physicians, London, UK (2002).
54. Brown JP, Josse RG: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167 (Suppl. 10), S1-S34 (2002).
55. Tanaka I, Oshima H: Importance of age in rate of incident fractures in glucocorticoid-induced osteoporosis. J. Bone Miner. Res. 20(Suppl. 1), S163 (2005) (Abstract).
56. Sambrook PN: Glucocorticoid osteoporosis. Curr Pharm. Des. 8 (21), 1877-1883 (2002).
57. Saag KG, Emkey R, Schnitzer TJ et al.: Alendronate for the prevention and treatment of glucocorticold-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339(5), 292-299 (1998).
58. Reid DM, Hughes RA, Laan RF et al.: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosterold-Induced Osteoporosts Treatment Study. J. Bone Miner. Res. 15 (6), 1006-1013 (2000).
59. Adachi JD, Roux C, Pitt PI et al.: A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J. Rheumatol. 27 (10), 2424-2431 (2000).
60. Adachi JD, Saag KG, Deimas PD et al.: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind. placebo-controlled extension trial. Arthritis Rheum. 44(1), 202-211 (2001).
61. Wallach S, Cohen S, Reid DM et al.: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int 67(4), 277-285 (2000).
62. Cohen D, Adachi JD: The treatment of glucocorticoid-induced osteoporosis. J. Steroid Biochem. Mol. Biol. 88(4-5), 337-349(2004).
63. Lau EM, Woo J, Chan YH, Li M: Alendronate for the prevention of bone loss in patients on Inhaled steroid therapy. Bone 29(6), 506-510 (2001).
64. Kasayama S, Fujita M, Goya K et al.: Effects of alendronate on bone mineral density and bone metabolic markets in postmenopausal asthmatic women treated with inhaled corticosteroids. Metab. Clin. Exp. 54(1), 85-90 (2005).
65. Tascioglu F, Colak O, Armagan O, Alatas O, Oner C: The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. Rheumatol. Int. 26(1), 21-29 (2005).
66. Silverman SL: Calcitonin. Biol. Pharm. Bull. 8, 946-951 (2000).
67. Adachi JD, Bensen WG, Bianchi F et al.: Vitamin D and calcium in the prevention of corticosteruid induced osteoporosis: a 3 year follow up. J. Rheumatol. 23(6), 995-1000 (1996).
68. Reginster JY, Kuntz D, Verdickt W et al.: Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos. Int. 1, 75-81 (1999).
69. Sambrook P, Birmingham 1, Kelly P et al.: Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N. Engl. J. Med. 328(24), 1747-1752 (1993).
70. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugweli P: Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst. Rev. 2, CD000952 (2000).
71. Franchimont N, Canalis E: Management of glucocorticoid induced osteoporosis in premenopausal women with autoinumme disease. Autoimmun. Rev. 2(4), 224-228 (2003).
72. Watts N, Freedholm D, Daifotis A: The clinical tolerability profile of alendronate. Int J. Clin. Pract. Suppl. 101, 51-61 (1999).
73. Schnitzer T, Bone HG, Crepaldi G et al.: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12(1), 1-12 (2000).
74. Kendler D, Kong AW, Fuieihan G et al.: Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48(3), 243-251 (2004).
75. Gourlay ML, Brown SA: Clinical considerations in premenopausal osteoporosis. Arch. Intern. Med. 164(6), 603-614 (2004).
76. Kanis A Melton LJ III, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis. J. Bone Miner. Res. 9(8), 1137-1141 (1994).
77. Khan AA, Syed Z: Bone densitometry in premenopausal women: synthesis and review. J. Clin. Densitom. 7(1), 85-92 (2004).
78. Writing Group for the ISCD Position Development Conference: Diagnosis of osteoporosis in men, premenopausal women, and children. J. Clin. Densitom. 7(1), 17-26 (2004).
79. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R: Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann. Rheum. Dir. 54(10), 801-806 (1995).
80. Kumagai S, Kawano S, Atsumi T et al.: Vertebral fracture and bone mineral density in women receiving high dose glucocorttcoids for treatment of autoimmune diseases. J. Rheumatol. 32(5), 863-869 (2005).
81. Yood RA, Harrold LR, Fish L et al.: Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch. Intern. Med 161 (10), 1322-1327 (2001).
82. Solomon DH, Katz IN, Jacobs JP, La Tourette AM, Coblyn J: Management of glucocorticoid-Induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheurnatology practice. Arblulas Rheum. 46(12), 3136-3142 (2002).
83. Arlot M, Meunier PJ, Boivin G et al.: Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J. Bone Miner. Res. 20(7), 1244-1253 (2005).